US-based medical technology company Edwards Lifesciences has unveiled its plans to spend $1.2bn to acquire JenaValve Technology and Endotronix.
JenaValve Technology is developing a transcatheter treatment for aortic regurgitation (AR).
The company recently reported positive outcomes from its US trial for treating symptomatic, severe AR in high-risk patients at the end of last year.
The acquisition will help Edwards Lifesciences to advance the treatment of aortic valve diseases.
Edwards Lifesciences expects US Food and Drug Administration (FDA) approval for the JenaValve Trilogy Heart Valve System by late 2025, marking the first approved therapy for AR patients.
Following an initial investment in 2016, the medical technology firm exercised its option to buy Endotronix, a provider of heart failure (HF) management solutions.
The acquisition will broaden Edwards Lifesciences’ structural heart portfolio into a new therapeutic domain aimed at meeting the unmet needs of HF patients.
Recently, Endotronix achieved FDA approval for Cordella, an implantable sensor for monitoring pulmonary artery pressure.
The sensor allows timely and targeted therapeutic interventions. A national coverage decision by CMS is anticipated in early 2025.
Edwards Lifesciences CEO Bernard Zovighian said: “These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world.
“We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”
With these acquisitions, Edwards Lifesciences expects to bolster its position in the structural heart innovation sector and aim for long-term growth. Minimal revenue from the acquisitions is anticipated for 2025.
Completion of the acquisitions is contingent upon fulfilling specific closing conditions, including obtaining necessary antitrust and foreign investment approvals.
Edwards Lifesciences is strengthening its mergers and acquisitions (M&A) capabilities following the announcement of a $4.2bn cash deal to sell its Critical Care business to BD last month.
Recent developments include Edwards Lifesciences’ acquisition of Innovalve, a mitral valve company, for $300m.
Additionally, the medical technology firm signed three agreements worth €15m with Affluent Medical to get rights to the latter’s Kalios adjustable mitral annulus and mitral valve technology.
